This article has Open Peer Review reports available.
Long-term experience of hyperbaric oxygen therapy for refractory radio- or chemotherapy-induced haemorrhagic cystitis
https://doi.org/10.1186/s12894-015-0035-4
© Degener et al.; licensee BioMed Central. 2015
Received: 9 January 2015
Accepted: 22 April 2015
Published: 8 May 2015
Abstract
Background
Radiotherapy and cyclophosphamide-induced haemorrhagic cystitis are rare but severe complications occurring in 3–6% of patients. Hyperbaric oxygen treatment (HBOT) has been demonstrated to be an effective treatment for haematuria not responding to conventional management. Only very few data exist for long-term follow-up after HBOT.
Methods
We retrospectively reviewed 15 patients referred for HBOT for haemorrhagic cystitis (HC). HBOT was performed for 130 min/day at a pressure of 2.4 atmospheres. We evaluated patient demographics, type of radio- and chemotherapy and characteristics of haematuria. The effect of HBOT was defined as complete or partial resolution of hematuria according to the RTOG/EORTC grade and Gray score.
Results
A total of 15 patients (12 after radiotherapy, two after chemotherapy and one patient with a combination of both) were treated with a median of 34 HBO treatments. Radiotherapy patients received primary, adjuvant, salvage and HDR radiotherapy (60 – 78 Gy) for prostate, colon or cervical cancer. The patient with combination therapy and both of the chemotherapy patients were treated with cyclophosphamide. First episodes of haematuria occurred at a median of 48 months after completion of initial therapy. The first HBOT was performed at a median of 11 months after the first episode of hematuria. After a median of a 68-month follow-up after HBOT, 80% experienced a complete resolution and two patients suffered a singular new minor haematuria (p < 0.00001). A salvage-cystectomy was necessary in one patient. No adverse effects were documented.
Conclusions
Our experience indicate that HBOT is a safe and effective therapeutic option for treatment-resistant radiogenic and chemotherapy-induced haemorrhagic cystitis. For a better evaluation prospective clinical trials are required.
Keywords
Background
Radiotherapy-induced haemorrhagic cystitis (RHC) after pelvic radiation therapy is a rare but known long-term complication which develops in 3–6.5% of patients. RHC can occur from 6 months to 20 years after radiation therapy [1-3]. Chemotherapy-induced haemorrhagic cystitis (CHC) can also cause chemotherapy-limiting haematuria (cyclophosphamide or others oxazaphosphorines) [4-7]. Since the introduction of Mesna (2-mercaptoethanesulfonic acid), a thiol compound, for uroprotection the incidence of CHC has decreased to less than 5% [5]. Despite the underlying cause, HC is a relevant impairment of the patients’ quality of life with often multiple and mostly emergency admissions to hospitals.
As for other severe haematurias, bladder irrigation is the primary treatment for HC. Different systemic or intravesical agents such as hyaluronic acid, aminocaproic acid, formalin or prostaglandins have been used, however with limited success [8]. As a consequence, bladder fulguration is repeatedly used as a therapeutic option to stop bleeding and blood is transfused when indicated. In the most severe cases selective embolization of the hypogastric arteries or salvage cystectomy with urinary diversion may be necessary [9].
Hyperbaric oxygen therapy (HBOT) is a promising but still extreme rarely-used therapeutic option for patients in whom the standard management has failed. By increasing the tissue oxygen level by up to 15-fold, HBOT promotes capillary angiogenesis which also increases the regeneration of damaged urothelium. Studies report success rates of 73 to 96% [1,3,10-13]. We present here our results of HBOT for the treatment of RHC and CHC.
Methods
We retrospectively reviewed all 23 patients treated with HBOT for haemorrhagic cystitis between 01/2002 and 10/2014 in two urological departments. In 15 patients a complete follow-up was achievable. Patient demographics were recorded, as was for RHC the total radiation dosage and the type of radiation therapy. Follow-up was ensured by outpatient contacts in the clinic and by cooperating ambulatories. Each patient gave informed consent and the study was approved by the institutional review committee of Witten/Herdecke University.
Evaluation of hematuria
Initially, all patients underwent permanent bladder irrigation and evacuation of blood clots. Urine cultures were set up before irrigation to detect infectious haematuria. When urine cleared after bladder irrigation patients underwent a cystoscopy or, in cases of heavy bleeding, a transurethral resection / fulguration to rule out an urothelial carcinoma (including carcinoma in situ). Additionally, the upper urinary tract was evaluated to exclude it as a source of bleeding.
Classification scores for chronic radio- and chemotherapy induced haemorrhagic cystitis | |||||
|---|---|---|---|---|---|
Radiotherapy | RTOG/ EORTC scale | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
Microscopic haematuria, requiring no medication; Minor telangiectasia | Moderate haematuria requiring medication; Moderate telangiectasia | Severe haematuria; Severe telangiectasia | Necrosis; Severe haemorrhagic cystitis | ||
Chemotherapy | Gray score | Grade 0 | Grade 1 | Grade 2 | Grade 3 |
Normal, no haematuria | Mild haematuria with telangiectasia or dilatation of the bladder vessels | Severe haematuria with mucosal haematomas | Severe haematuria with intravesical clots | ||
Hyperbaric oxygen therapy
Clinical characteristics of patients and details of CHC and RHC and HBO treatment
Sex | Age/Therapy | Age/End of Follow-up | Diagnosis | Treatment | HBO IndicationIndikation | End of Therapy | Time till Haematuria [m] | RTOG/Gray before HBOT | Admissions to Hospital | Number blood transfusions | Duration till HBO [m] | HBO Treatments | Follow Up [m] | Events/Follow-up | RTOG/Gray after HBO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
M | 68 | 70 | PCA | adj | RC | 08/2008 | 34 | 3 | 5 | 0 | 4 | 40 | 33 | no relapse | 0 |
M | 82 | 86 | PCA | prim | RC | 07/2004 | 54 | 3 | 3 | 0 | 15 | 24 | 53 | no relapse | 0 |
M | 73 | 81 | PCA | HDR | RC | 08/2002 | 11 | 4 | 4 | 2 | 33 | 24 | 100 | 1x haematuria 2007 | 3 |
W | 71 | 83 | CCA | adj | RC | 07/1997 | 30 | 3 | 3 | 0 | 28 | 128 | 142 | no relapse | 0 |
M | 80 | 86 | PCA | prim | RC | 07/1998 | 5 | 4 | 2 | 2 | 110 | 40 | 78 | no relapse | 0 |
M | 71 | 76 | PCA | adj | RC | 01/1999 | 76 | 4 | 2 | 1 | 36 | 35 | 28 | no relapse, †2010 | 0 |
W | 86 | 90 | UCA | adj | RC | 01/1990 | 234 | 4 | 3 | 2 | 0 | 6 | 29 | no relapse, †2012 | 0 |
M | 80 | 83 | PCA | adj | RC | 01/2000 | 124 | 4 | 3 | 3 | 1 | 51 | 16 | SRC 2010, †2012 | 4 |
M | 65 | 72 | PCA | adj | RC | 03/2000 | 50 | 4 | 3 | 1 | 30 | 26 | 94 | no relapse | 0 |
M | 61 | 63 | PCA | sal | RC | 02/2010 | 20 | 4 | 3 | 4 | 7 | 20 | 133 | no relapse | 0 |
M | 22 | 33 | RPSS | comb | RC/CC | 01/1999 | 43 | 4 | 2 | 12 | 11 | 34 | 28 | no relapse | 0 |
M | 73 | 78 | PCA | sal | RC/RP | 07/2007 | 14 | 3 | 2 | 2 | 1 | 48 | 68 | no relapse | 0 |
M | 65 | 71 | PCA | adj | RC/RP | 07/2003 | 48 | 4 | 3 | 2 | 3 | 20 | 49 | no relapse, †2011 | 0 |
W | 49 | 56 | LE | prim | CC | 01/1974 | 362 | 3 | 4 | 0 | 40 | 40 | 86 | 1x haematuria 2008 | 3 |
M | 39 | 49 | WG | prim | CC | 01/1993 | 120 | 4 | 3 | 1 | 4 | 17 | 136 | no relapse | 0 |
Exterior and interior view on the pressure chamber for max. 12 persons.
Diagram of the therapy scheme TS 240–90. “Air” is defined as normal ambient air with 21% (v/v) oxygen. “Oxygen” is defined as the application of 100% (v/v) oxygen. The pressure [atmosphere] is plotted on the y-axis, the treatment time [min] on the x-axis (adopted from [24]).
The effect of HBOT was defined as complete (no further macro-haematuria until completion of follow-up) or partial resolution of haematuria (defined as a lower RTOG/EORTC or Gray score than before HBOT).
Results
In 15 patients (12 males, 3 females) undergoing HBOT for therapy-resistant haemorrhagic cystitis between 2002 and 2014 a complete retrospective follow-up was achieved. Additionally, two patients suffered from haemorrhagic proctitis. At the beginning of HBOT the age ranged from 22 to 86 years (mean age 71). At the end of follow-up the age ranged from 33 to 90 years (mean age 76 y).
Radiotherapy was performed owing to prostate (10 patients, 67%), colon or cervical cancer (1 patient each, 7%). One patient underwent combined radio-chemotherapy owing to retroperitoneal synovial sarcoma (with Ifosfamide, ISF) and two patients (13%) were treated with cyclophosphamide for Wegener’s granulomatosis or Lupus erythematosus.
In 7 patients (47%) radiotherapy was performed as an adjuvant because of prostate, colon or cervical cancer (60–64 Gy). Primary and salvage radiation was applied to two patients (13%) for prostate cancer (66 and 70 Gy) and one patient (7%) was treated with HDR brachytherapy (78 Gy) for prostate cancer. The radiation dose of the patient with retroperitoneal synovial sarcoma was 66 Gy.
The first episodes of haematuria occurred between 5 and 362 months (median 48 months) after the beginning of radiation or chemotherapy. A median of three (2 – 5) admissions to the hospital and up to seven outpatient treatments were necessary. According to the RTOG/EORTC score haemorrhagic complication Grade 4 occurred in nine patients (60%) and Grade 3 in four (27%). Patients with CHC had haemorrhagic complication Grade 3 or 4 respectively (Gray score). Blood transfusions (between 1 and 12 units) were necessary in 11 patients (73%).
In all patients urothelial malignancy was excluded by histology. At least one bladder fulguration was performed in every case in order to stop the bleeding but no patient received any intravesical instillation therapy.
When HC was resistant to conventional therapy (without instillation therapy) HBOT was initiated, in a median of eleven months (0 – 110) after the first episode of haematuria. Between 6 and 128 HBOT sessions (mean 34) were necessary to achieve a total resolution of haematuria. In all HBOT sessions the partial pressure of oxygen measured percutaneously was increased to 1250–1480 mmHg.
Follow-up ranged from 16 to 142 months (mean 68). In 12 patients (80%) a total resolution of the HC could be achieved without any further haematuria. In two patients (13%) bladder irrigation had to be re-performed once for a singular recurrence of haematuria (RTOG/EORTC Grade 3). Changes in RTOG/EORTC scores were statistically significant (p < 0.00001).
In one case a salvage cystectomy with urinary diversion (ileum conduit) was necessary owing to a fulminant bleeding episode. The overall success rate was 93%. The radiogenic proctitis completely recovered in both cases. No side effects were noted in any patient.
Discussion
Radiation and cyclophosphamide-induced HC is a severe and potentially life threatening complication. Management can be highly challenging with well-known urological treatment options. It is to be expected that the number of radiation therapies will increase during the next decades [17]. In parallel a rise in complications and side effects, such as RHC, can be expected. The results of this study suggest that HBOT is a promising option in therapy-resistant HC with a success rate of more than 90%.
In both CHC and RHC the acute reaction on urothelial damage is an inflammatory response causing oedema, ulceration, neovascularisation and haemorrhagic necrosis. This is usually limited to the treatment period.
In CHC urotoxicity is caused directly by the renal excretion of acrolein, metabolites of oxazaphosphorine alkylated drugs. There is no clear dose-related relationship. Since the 1970s the prophylactic application of Mesna has been used as a standard protocol for prevention of haemorrhagic complications. It neutralises acrolein and its toxic effects to the urothelium. The incidence of CHC is reduced from about 68% to about 5% [5].
In RHC urothelial damage is caused by radiolysis of water. The concentration of activated free oxygen radicals increases; as these are highly reactive, they cause cell membrane injury by lipid peroxidation, which induces immediate cell death. Additionally, direct (by radiation energy) and indirect (by oxygen radicals) DNA damage causes replication failures resulting in delayed cell death [8]. This damage is dose-related.
This acute reaction can escalate into a chronic endarteritis which seems to be the determining pathology of late-onset RHC and has been described as the “three-H model”: the progressive endarteritis and vascular rarefaction (hypovascular) results in critical ischaemia (hypoxia) with a reduction in oxygen concentration of up to 70-80%. Ischaemia of the mucosal tissue can lead to necrosis and sloughed off cells because of impaired healing capacity. A compensatory teleangiectasia develops and causes (persistent) haematuria. Finally, fibrotic repair processes can lead to impaired bladder capacity (hypocellular) [3,11]. This process can still become relevant up to 20 years after radiation therapy [2]. In our study haematuria occurred in a median of 41 months after completion of radiation therapy. This is within the range of previously described periods of 35–48 months [1,2,8,10].
Tissue oxygen supply occurs primarily via diffusion from the capillaries by significantly increasing the physically dissolved oxygen in the plasma (100% O2 pressure of 1.4 atmosphere). HBOT improves the local and regional tissue oxygen supply. Our results demonstrate a drastically increased pO2 in the tissue from 1250 to 1480 mmHg from percutaneous measurements. By increasing pO2, macrophages, fibroblasts and granulocytes may resume their normal function and mediate repair processes. In addition, HBOT directly induces neo-angiogenesis, whereby 80% of the normal capillary density can be achieved. Furthermore HBOT causes anti-oedematous vasoconstriction without secondary ischaemic hypoxia [18-20].
Hyperbaric oxygen in patients with severe RHC or CHC not responding to conventional urological treatment is an extremely rare and not yet standardised treatment option.
In RHC different research groups and we have reported success rates between 75 and 96% in both prospective and retrospective study designs [10,13,19,21-23]. In contrast to our study, other cohorts have varied between 13–60 patients with only short follow-up periods of 12–30 months.
We could demonstrate a success rate of 90% even after a median long-term follow-up period of 68 months, confirming the excellent long-term results reported by Nakada et al. whose success rate was 75-88% [12].
Only a few cases patients with CHC have been reported. One of the larger series with six CHC patients reported a 100% success rate after 11 to 36 months of follow-up (although they noted that in one patient haematuria recurred after three months) [24]. In other reported case reports a complete loss of haematuria occurred after a follow-up period of 11–36 months [7,24-26].
The main advantage of this therapy is that there are no severe side-effects. The most common adverse effects of HBOT are middle ear or sinus barotraumas requiring myringotomy in up to 5% [27]. Reversible myopia has also been described as a dose-dependent HBOT side effect [27]. Our study, as many other reports, did not show any adverse effects of HBTO.
So far variable success of HBOT has been discussed without any clear results, mainly because of the small sample size in most series.
In RHC the total radiation dose seems to have an influence on HBOT success: generally, complications such as RHC begin at a total dosage of 45–55 Gy and increase significantly at a cumulative dose of ≥60 Gy (≥5% with late effects) [28]. Nakada et al. showed a significantly better HBOT success in patients exposed to lower radiation doses (62Gy vs. 76Gy, p < 0.001). In addition del Pizzo et al. reported relatively poor HBOT long-term success rates (27% after 5 years) in patients with high dosage radiotherapy (75Gy) [29]. In the present study most of the patients received a cumulative dose between 60 – 66Gy. One patient with high dose therapy (78 Gy) suffered one unique relapse of haematuria.
Some authors discuss that there might be an influence of the number of HBOT sessions on the therapeutic success in RHC. Most of the studies applied between 30 and 40 treatment sessions [13,19,21,29] which is comparable to our data with a median of 34 treatments. The significantly higher number of HBOTs (62) may be the reason for the excellent long-term success in Nakada’s study compared with a study with a success rate of 64% after only 14 HBOTs [30]. The few existing data suggest that fewer HBOTs are sufficient in CHC patients. The reported series of six CHC cases required a median of 27 HBOTs, other published cases between 14 and 40 treatments [7,24-26].
The period of time between the onset of haematuria and the beginning of HBOT is discussed as another success factor for RHC. In some studies, patients with a shorter pre-treatment interval (6–8 months) showed significantly better results on HBOT (p <0.001) [12,13]. We could not demonstrate any relationship between the time to beginning of HBOT and its success. This is most probably because, as CHC is the more acute event, HBOT was started at a mean of 47 days after the onset of symptoms. However, intervals of up to four months between first admission and the beginning of HBOT have been described [24].
Finally the influence of patient age is controversially discussed. Some studies suggest that younger patients (≤70 years) have higher success rates. Other studies, as well as ours, have not found any correlation between age and HBOT success. Furthermore, in CHC patients a complete remission of haematuria is reported in cases aged from 15 to 82 years [1,12,13,24-26].
The costs amount to approximately €200 per HBOT session. Accordingly, the median costs per patient in this study were €6,800 (34 HBOT sessions). The costs are comparable to a cost-analysis case study from Australia which showed HBOT to provide major health cost savings [31].
Our study, as many others, is certainly limited by the small study population and the retrospective design. Furthermore different treatment protocols reduce the comparability of treatment outcomes. Prospective trials would be desirable for further evaluation but the first planned prospective and randomized study (initiated by the Baromedical Research Foundation) was cancelled because of poor recruitment (NCT00134628). Nevertheless, we believe that our results show the long-term efficiency and safety of this therapy option in patients suffering from radiation- and cyclophosphamide-induced haemorrhagic cystitis.
Conclusions
Our data suggest that hyperbaric oxygen therapy is a safe and simple therapy option with a long-term success rate of approximately 90% with hardly any side-effects. Therefore HBOT should be considered more often in cases of severe haemorrhagic cystitis induced by radiation and/or cyclophosphamide.
Abbreviations
- HC:
-
Hemorrhagic Cystitis
- HBOT:
-
Hyperbaric Oxygen Treatment
- RHC:
-
Radiotherapy-induced Hemorrhagic Cystitis
- CHC:
-
Chemotherapy-induced Hemorrhagic Cystitis
- RTOG:
-
Radio Therapy Oncology Group
- EORTC:
-
European Organisation for Research and Treatment of Cancer
- ECG:
-
Electrocardiography
- PCA:
-
Prostate Cancer
- CCA:
-
Colon Cancer
- UCA:
-
Uterine / Cervical Cancer
- RPSS:
-
Retroperitoneal Synovial Sarcoma
- LE:
-
Lupus Erythematosus
- WG:
-
Wegener’s Granulomatosis
- Adj:
-
Adjuvant Radiation
- Prim:
-
Primary Radiotherapy
- HDR:
-
High-Dose Rate
- Sal:
-
Salvage Radiotherapy
- Comb:
-
Combined Chemoradiation
- RC:
-
Radiotherapy-induced Cystitis
- RP:
-
Radiotherapy-induced Proctitis
- CC:
-
Chemotherapy – induced Cystitis
- SRC:
-
Salvage Cystectomy
Declarations
Authors’ Affiliations
References
- Corman JM, McClure D, Pritchett R, Kozlowski P, Hampson NB. Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen. J Urol. 2003;169(6):2200–2.View ArticlePubMedGoogle Scholar
- Levenback C, Eifel PJ, Burke TW, Morris M, Gershenson DM. Hemorrhagic cystitis following radiotherapy for stage Ib cancer of the cervix. Gynecol Oncol. 1994;55(2):206–10.View ArticlePubMedGoogle Scholar
- Mendenhall WM, Henderson RH, Costa JA, Hoppe BS, Dagan R, Bryant CM, Nichols RC, Williams CR, Harris SE, Mendenhall NP: Hemorrhagic Radiation Cystitis. American journal of clinical oncology 2013. [Epub ahead of print].Google Scholar
- Lima MV, Ferreira FV, Macedo FY, De Castro Brito GA, Ribeiro RA. Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis. Cancer Chemother Pharmacol. 2007;59(5):643–50.View ArticlePubMedGoogle Scholar
- Korkmaz A, Oter S, Deveci S, Goksoy C, Bilgic H. Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs. J Urol. 2001;166(3):1119–23.View ArticlePubMedGoogle Scholar
- Kalayoglu-Besisik S, Abdul-Rahman IS, Erer B, Yenerel MN, Oguz FS, Tunc M, et al. Outcome after hyperbaric oxygen treatment for cyclophosphamide-induced refractory hemorrhagic cystitis. J Urol. 2003;170(3):922.View ArticlePubMedGoogle Scholar
- Hughes MJ, Davis FM, Mark SD, Spearing RL. Hyperbaric oxygen for cyclophosphamide-induced cystitis. Br J Haematol. 2002;119(2):575.View ArticlePubMedGoogle Scholar
- Smit SG, Heyns CF. Management of radiation cystitis. Nat Rev Urol. 2010;7(4):206–14.View ArticlePubMedGoogle Scholar
- Linder BJ, Tarrell RF, Boorjian SA. Cystectomy for refractory hemorrhagic cystitis: contemporary etiology, presentation and outcomes. J Urol. 2014;192(6):1687–92.View ArticlePubMedGoogle Scholar
- Bevers RF, Bakker DJ, Kurth KH. Hyperbaric oxygen treatment for haemorrhagic radiation cystitis. Lancet. 1995;346(8978):803–5.View ArticlePubMedGoogle Scholar
- Crew JP, Jephcott CR, Reynard JM. Radiation-induced haemorrhagic cystitis. Eur Urol. 2001;40(2):111–23.View ArticlePubMedGoogle Scholar
- Nakada T, Nakada H, Yoshida Y, Nakashima Y, Banya Y, Fujihira T, Karasawa K: Hyperbaric Oxygen Therapy for Radiation Cystitis in Patients with Prostate Cancer: A Long-Term Follow-Up Study. Urologia internationalis. 2012;89(2):208–14.Google Scholar
- Chong KT, Hampson NB, Corman JM. Early hyperbaric oxygen therapy improves outcome for radiation-induced hemorrhagic cystitis. Urology. 2005;65(4):649–53.View ArticlePubMedGoogle Scholar
- Peeters ST, Heemsbergen WD, Van Putten WL, Slot A, Tabak H, Mens JW, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61(4):1019–34.View ArticlePubMedGoogle Scholar
- Gray KJ, Engelmann UH, Johnson EH, Fishman IJ. Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy. J Urol. 1986;136(2):497–500.PubMedGoogle Scholar
- Marx RE, Johnson RP. Problem wounds in oral and maxillofacial surgery: The role of hyperbaric oxygen. In: Davis JC, Hunt TK, editors. Problem Wounds: The Role of Oxygen edn. New York: Elsevir Science Publishing; 1988. p. 65–123.Google Scholar
- Frodin JE, Jonsson E, Moller T, Werko L. Radiotherapy in Sweden–a study of present use in relation to the literature and an estimate of future trends. Acta Oncol. 1996;35(8):967–79.View ArticlePubMedGoogle Scholar
- Anderson LH, Wilson B, Herring RF, Mehm WJ. Influence of intermittent hyperoxia on hypoxic fibroblasts. J Hyperbaric Med. 1992;7:103–14.Google Scholar
- Weiss JP, Mattei DM, Neville EC, Hanno PM. Primary treatment of radiation-induced hemorrhagic cystitis with hyperbaric oxygen: 10-year experience. J Urol. 1994;151(6):1514–7.PubMedGoogle Scholar
- Muhonen A, Haaparanta M, Gronroos T, Bergman J, Knuuti J, Hinkka S, et al. Osteoblastic activity and neoangiogenesis in distracted bone of irradiated rabbit mandible with or without hyperbaric oxygen treatment. Int J Oral Maxillofac Surg. 2004;33(2):173–8.View ArticlePubMedGoogle Scholar
- Oscarsson N, Arnell P, Lodding P, Ricksten SE, Seeman-Lodding H. Hyperbaric oxygen treatment in radiation-induced cystitis and proctitis: a prospective cohort study on patient-perceived quality of recovery. Int J Radiat Oncol Biol Phys. 2013;87(4):670–5.View ArticlePubMedGoogle Scholar
- Degener S, Strelow H, Pohle A, Lazica DA, Windolf J, Zumbe J, et al. Hyperbaric oxygen in the treatment of hemorrhagic radiogenic cystitis after prostate cancer. Der Urologe Ausg A. 2012;51(12):1735–40.View ArticlePubMedGoogle Scholar
- Yoshida T, Kawashima A, Ujike T, Uemura M, Nishimura K, Miyoshi S. Hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis. International journal of urology : official journal of the Japanese Urological Association. 2008;15(7):639–41.View ArticleGoogle Scholar
- Davis M, MacDonald H, Sames C, Nand K. Severe cyclophosphamide-induced haemorrhagic cystitis treated with hyperbaric oxygen. The New Zealand medical journal. 2011;124(1340):48–54.PubMedGoogle Scholar
- Shameem IA, Shimabukuro T, Shirataki S, Yamamoto N, Maekawa T, Naito K. Hyperbaric oxygen therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis. Eur Urol. 1992;22(3):263–4.PubMedGoogle Scholar
- Yazawa H, Nakada T, Sasagawa I, Miura M, Kubota Y. Hyperbaric oxygenation therapy for cyclophosphamide-induced haemorrhagic cystitis. Int Urol Nephrol. 1995;27(4):381–5.View ArticlePubMedGoogle Scholar
- Tahir AR, Westhuyzen J, Dass J, Collins MK, Webb R, Hewitt S, et al. Hyperbaric oxygen therapy for chronic radiation-induced tissue injuries: Australasia’s largest study. Asia Pac J Clin Oncol. 2015;11(1):68–77.View ArticlePubMedGoogle Scholar
- Roswit B, Malsky SJ, Reid CB. Severe radiation injuries of the stomach, small intestine, colon and rectum. Am J Roentgenol Radium Ther Nucl Med. 1972;114(3):460–75.View ArticlePubMedGoogle Scholar
- Del Pizzo JJ, Chew BH, Jacobs SC, Sklar GN. Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen: long-term followup. J Urol. 1998;160(3 Pt 1):731–3.PubMedGoogle Scholar
- Mathews R, Rajan N, Josefson L, Camporesi E, Makhuli Z. Hyperbaric oxygen therapy for radiation induced hemorrhagic cystitis. J Urol. 1999;161(2):435–7.View ArticlePubMedGoogle Scholar
- Smart D, Wallington M. A cost-analysis case study of radiation cystitis treatment including hyperbaric oxygen therapy. Diving and hyperbaric medicine. 2012;42(2):92–7.PubMedGoogle Scholar
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
